Michael Martin Breen - Jan 13, 2021 Form 3 Insider Report for GT Biopharma, Inc. (GTBP)

Role
Director
Signature
/s/ Michael Martin Bree
Stock symbol
GTBP
Transactions as of
Jan 13, 2021
Transactions value $
$0
Form type
3
Date filed
11/12/2021, 11:01 AM
Next filing
Nov 12, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding GTBP 10% Senior Convertible Debenture Jan 13, 2021 Common Stock $3.40 Direct F1
holding GTBP 10% Senior Convertible Debenture Jan 13, 2021 Common Stock $3.40 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects a 10% Senior Convertible Debenture in the face amount of $100,000. While the maturity date of the Debenture was September 7, 2019, the Registrant did not repay the Debenture on the maturity date and the Debenture remained outstanding. Per the provisions of the Debenture, outstanding principal and interest were convertible at a per share price of $3.40 (which reflects the applicable conversion price on a post-reverse split basis).
F2 Reflects a 10% Senior Convertible Debenture in the face amount of $30,000. Per the provisions of the Debenture, outstanding principal and interest were convertible at a per share price of $3.40 (which reflects the applicable conversion price on a post-reverse split basis)